Fate Therapeutics

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2024

Fate Therapeutics Reports Surge in Q1 Revenue Amid Collaboration Challenges

Fate Therapeutics faced challenges in Q1 but achieved significant revenue growth. They maintain a strong financial position and are focused on advancing key program initiatives. However, uncertainties around clinical updates and the termination of a collaboration pose immediate challenges.

FATE reports Q2 revenue decline, progresses in innovative cell therapies

FATE reported a sharp decline in revenue and a net loss for the quarter, while also highlighting progress in its innovative cell therapy programs. The company faces financial challenges but has opportunities for growth through its advanced clinical trials and focus on cell therapy.

Fate Therapeutics reports Q3 financials, focuses on oncology and autoimmunity

Fate Therapeutics is focused on advancing its product platforms in oncology and autoimmunity, with multiple clinical studies underway. While facing financial challenges, the company's strong cash position and cost management efforts provide a foundation for future growth. The exploration of cell therapies in autoimmunity presents both challenges and opportunities for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BJ`s Wholesale Club Holdings Inc

Golar LNG

Chart Industries

Health Catalyst Inc

II-VI Incorporated

LivePerson

Nevro

PDC Energy Inc

Papa John's

QTS Realty Trust

If you desire growth, then your sights should be set on small-cap stocks. These 11 have attracted the gaze of dozens of Wall Street's best minds.

11 Small-Cap Stocks the Analysts Love for 2021

SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of 5,122,807 shares of its common stock, which included 701,754 shares that were issued pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $85.50 per share. In addition, in lieu of common stock to certain investors, the Company announced the closing of an underwritten public offering of pre-funded warrants to purchase 257,310 shares of its common stock at a purchase price of $85.499 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. Aggregate net proceeds from this offering are expected to be approximately $432 million after deducting underwriting discounts and commissions and other estimated offering expenses. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies of its product candidates, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of its new facility, the conduct of preclinical research and development, and for general corporate purposes.

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters' Option to Purchase Additional Shares

Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Fate Therapeutics (FATE) Stock?

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of 4,421,053 shares of its common stock at a public offering price of $85.50 per share. In addition, in lieu of common stock to certain investors, the Company announced the pricing of an underwritten public offering of pre-funded warrants to purchase 257,310 shares of its common stock at a purchase price of $85.499 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. This represents an aggregate offering of approximately $400 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 701,754 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected to be approximately $376 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters' option. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies of its product candidates, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of its new facility, the conduct of preclinical research and development, and for general corporate purposes. All shares of common stock and pre-funded warrants to be sold in the offering are being offered by Fate Therapeutics. The offering is expected to close on or about January 8, 2021, subject to customary closing conditions.

Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

BridgeBio Pharma Inc

Editas Medicine

Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.

3 Biotech Stocks That Could Double Your Money in 2021

SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of $350 million of shares of common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies of its product candidates, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of its new facility, the conduct of preclinical research and development, and for general corporate purposes. In connection with the offering, Fate Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock offered in the public offering. All shares of common stock to be sold in the offering will be offered by Fate Therapeutics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock

Moderna

Mersana Therapeutics

Intellia Therapeutics

Ultragenyx Pharmaceutical

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

5 Biotech Stocks That Have Gained More Than 200% in 2020

FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.

FATE Surges More Than 152% in Three Months: Here's Why?

The biotech's natural killer cell therapies have real potential.

Here's Why Fate Therapeutics' Data Produced a 38% Jump in the Stock Price

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Fate Therapeutics (FATE) Looks Good: Stock Adds 9.4% in Session

Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.

Fate (FATE) Surges on Favorable Phase I Data on FT596 at ASH

The stock price of Fate Therapeutics Inc (NASDAQ: FATE) has increased by 37.8% (from $60.79 on December 6 to $83.77 on December 7). This is why.

Fate Therapeutics Stock Price Increases 37.8%: Why It Happened

The biotech reported great news on Friday and Saturday for two of its cancer immunotherapy candidates.

Why Fate Therapeutics Stock Is Skyrocketing Today

Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells

Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

Why Is Fate Therapeutics (FATE) Up 21.8% Since Last Earnings Report?

3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response

Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will host a virtual event entitled “The Power of hnCD16” on Friday, December 4, 2020 at 4:30 PM EDT.

Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences:

Fate Therapeutics Announces Participation in Upcoming Investor Conferences

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript

First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma

Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will participate in a fireside chat at the Jefferies Cell Therapy Virtual Summit on Tuesday, October 6, 2020 and 2:30 p.m. E.T.

Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit

SAN DIEGO, Sept.  04, 2020  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences:

Fate Therapeutics Announces September Investor Events

SAN DIEGO, Aug.  19, 2020  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Edward Dulac has been appointed Chief Financial Officer. Mr. Dulac comes to the Company from Celgene Corporation, where he most recently served as Vice President, Business Development & Strategy, and brings an extensive array of biopharmaceutical experience having served for over 20 years in positions in finance, business development, and product portfolio strategy.

Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2020 Results - Earnings Call Transcript

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -75.00% and -73.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Fate Therapeutics Stock (FATE)